Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Liabilities (2016 - 2025)

Anaptysbio filings provide 10 years of Total Liabilities readings, the most recent being $327.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 20.77% year-over-year to $327.2 million, compared with a TTM value of $327.2 million through Dec 2025, down 20.77%, and an annual FY2025 reading of $327.2 million, down 20.77% over the prior year.
  • Total Liabilities hit $327.2 million in Q4 2025 for Anaptysbio, down from $382.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $417.5 million in Q2 2024, with the low at $14.5 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $359.4 million (2023), compared with a mean of $310.1 million.
  • The sharpest move saw Total Liabilities crashed 38.84% in 2021, then skyrocketed 1934.02% in 2022.
  • Year by year, Total Liabilities stood at $286.6 million in 2021, then rose by 21.5% to $348.3 million in 2022, then rose by 4.6% to $364.3 million in 2023, then rose by 13.36% to $413.0 million in 2024, then decreased by 20.77% to $327.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $327.2 million, $382.5 million, and $380.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.